Sign In
Buy CNSP
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026
ESCAPE Bio to Present at the Bank of America Securities Virtual Health Care Conference
12:00am, Monday, 11'th May 2020
ESCAPE Bio, Inc., a precision neurology company, today announced that Julie Anne Smith, Chief Executive Officer, will present at the Bank of America S
Investor Alert: Kaplan Fox Investigates CNS Pharmaceuticals
09:10pm, Friday, 08'th May 2020
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CNS Pharmaceuticals, Inc. ("CNS" or the "Company") (NASDAQ: CNSP). Investors who purchased CNS securit
SEC Puts the Kibosh on 3 Penny Stocks Hawking a Miracle Anti-Coronavirus Drug
12:35pm, Wednesday, 06'th May 2020
Since early February, the U.S. Securities and Exchange Commission has issued a series of warnings to investors to beware of companies hawking miracle
Cambridge Cognition Holdings make considerable progress in commercial and product development - DirectorsTalk
06:14am, Tuesday, 05'th May 2020
Cambridge Cognition Holdings plc (LON:COG), which develops and markets neuroscience technology to assess brain health, announced today its unaudited preliminary results for the year ended 31 Decemb
CNS Pharmaceuticals Announces Trading Halt
11:12pm, Monday, 04'th May 2020
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and c
SEC takes action against three more companies over COVID-19 claims
07:51pm, Monday, 04'th May 2020
The Securities and Exchange Commission temporarily halted trading in three more stocks on Monday because of questions regarding the accuracy of information...
Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett Syndrome
12:00am, Monday, 04'th May 2020
Newron Pharmaceuticals announced today that top-line results from its STARS clinical study did not meet primary or secondary efficacy variables.
U.S. IPO Week Ahead: GAN Bets On Itself In A One-IPO Week
08:11pm, Saturday, 02'nd May 2020
Just one IPO is scheduled for the week ahead, though there are a handful of deals in the IPO pipeline that are primed for May public offerings. Internet gamblin
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
12:00pm, Thursday, 30'th Apr 2020
The US Phase 2 trial Sponsor will be CNS and the Polish Phase 2 trial Sponsor will be WPD, a Polish corporation founded by Professor Waldemar Priebe, founder of both WPD and CNS. The Company expects
CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
12:00pm, Thursday, 30'th Apr 2020
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and c
VANCOUVER, British Columbia, April 24, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.
CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin
12:00pm, Thursday, 23'rd Apr 2020
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has filed an applica
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO, John M. Climaco, wi
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
11:00am, Tuesday, 21'st Apr 2020
VANCOUVER, British Columbia, April 21, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its.
